Reports

P&R: Risk and Opportunity in Pharmaceutical deal making

Successful deal making has drug valuation at its heart; however, valuation in deal making is not an exact science. Furthermore, health economic considerations that drive reimbursement decisions will play an increasing make-or-break role in new drug planning. Smarter deal making is vital to the efficiency of the pharmaceutical business and pricing and reimbursement awareness is integral to that smarter deal making. This report covers those essential market-changing initiatives which make tomorrow’s drug market different from that of today.